Coronary Stent Restenosis in Patients Treated With Cilostazol | Zendy

John S. Douglas | Zendy; David R. Holmes | Zendy; Dean J. Kereiakes | Zendy; Cindy L. Grines | Zendy; Elizabeth H. Block | Zendy; Ziyad M.B. Ghazzal | Zendy; Douglas C. Morris | Zendy; Henry Liberman | Zendy; Karen M. Parker | Zendy; Claudine Jurkovitz | Zendy; Nancy Murrah | Zendy; Jovonne K. Foster | Zendy; Pamela Hyde | Zendy; G.B. John Mancini | Zendy; William S. Weintraub | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Coronary Stent Restenosis in Patients Treated With Cilostazol

Author(s) -

John S. Douglas,

David R. Holmes,

Dean J. Kereiakes,

Cindy L. Grines,

Elizabeth H. Block,

Ziyad M.B. Ghazzal,

Douglas C. Morris,

Henry Liberman,

Karen M. Parker,

Claudine Jurkovitz,

Nancy Murrah,

Jovonne K. Foster,

Pamela Hyde,

G.B. John Mancini,

William S. Weintraub

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.104.530097

Subject(s) - medicine , cilostazol , restenosis , cardiology , stent , coronary stent , aspirin

Restenosis after implantation of coronary artery stents remains a significant clinical problem. We undertook a randomized, double-blind, placebo-controlled trial to determine whether cilostazol, a drug that suppresses intimal proliferation, would reduce renarrowing in patients after stent implantation in native coronary arteries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research